

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BioClonetics Incorporated	01/19/2010
RECEIVING PARTY DATA	
Name:	BioClonetics Immunotherapeutics, Inc.
Street Address:	1756 Bison Meadows Lane
City:	Heath
State/Country:	TEXAS
Postal Code:	75032
PROPERTY NUMBERS Total: 4	
Property Type	Number
Patent Number:	5459060
Patent Number:	5777074
Patent Number:	6008044
Patent Number:	6083504
CORRESPONDENCE DATA	
Fax Number:	(214)739-5209
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	214-292-8302
Email:	ghansen@hemlaw.org
Correspondent Name:	Eugenia S. Hansen
Address Line 1:	1717 Main Street
Address Line 2:	Comerica Bank Tower Suite 2500
Address Line 4:	Dallas, TEXAS 75201
ATTORNEY DOCKET NUMBER:	BCLN 00201 PTPV
NAME OF SUBMITTER:	Eugenia S. Hansen

OP \$160.00 5459060

501069617

PATENT
REEL: 023810 FRAME: 0474

Total Attachments: 3

source=Patent Assignment (2)#page1.tif

source=Patent Assignment (2)#page2.tif

source=Patent Assignment (2)#page3.tif

ASSIGNMENT AGREEMENT

WHEREAS, BioClonetics Incorporated ("Assignor"), a Texas corporation having its principal place of business in Dallas, Texas, is the owner of the entire right, title and interest to certain issued patents and inventions disclosed in patents and disclosures listed and contained in the attached Schedule A, and to all patents that may issue therefrom (herein all referenced as the "Inventions"), and

AND WHEREAS, BioClonetics Immunotherapeutic, Inc. ("Assignee"), a Texas corporation having its principal place of business in Heath, Texas, is desirous of acquiring the entire right, title and interest in and to the Inventions and to all patents that may issue therefrom, in the United States and throughout the world,

NOW, THEREFORE, for good and valuable consideration, the sufficiency of and receipt of which is hereby acknowledged, and intending to be legally bound hereby,

Assignor hereby assigns and transfers to Assignee the entire right, title and interest in and to the Inventions, including, but not limited to, any patents or pending applications, currently pending or later filed, foreign or domestic, which claim the benefit of priority directly or indirectly from any of the Inventions, as well as any patents which may issue therefrom, and any reexaminations, reissues, continuations, continuations-in-part, divisions, renewals and extensions of the foregoing, all rights of action arising from any patents, all claims for damages by reason of past infringement and the right to sue and collect damages for such infringements, to be held and enjoyed by the Assignee for its own use and benefit and for its successors and assigns as the same would have been held by Assignor had this assignment not been made.

Assignor represents and warrants to the Assignee that it owns the right, title and interest in the Inventions.

Assignor represents and warrants to the Assignee that Assignor has no knowledge of any prior claim in relation to the Inventions and to its knowledge (actual or constructive) no litigation is pending in relation to the ownership of the Inventions.

Assignor represents and warrants that it has no notice that any third party intends to commence legal proceedings in relation to the Inventions.

Assignor agrees to indemnify and hold harmless the Assignee from and against any and all third party claims, demands, losses, damages and reasonable expenses (including, without limitation, reasonable legal fees) arising from a challenge to the ownership of such Inventions by Assignor as of the date of this Assignment.

IN TESTIMONY WHEREOF, I have hereunto set my hand this 19th day of January, 2010.




Charles S. Cotropia, Vice-President
BioClonetics Incorporated

State of Texas §
 §
County of Dallas §

On this 19th day of January, 2010, before me, a Notary Public in and for the State of Texas, personally appeared Charles S. Cotropia, to me well known and known by me to be the person of the above name who signed the foregoing instrument and acknowledged the same to be his own free act and deed.



Notary Public, State of Texas



SCHEDULE A
To Assignment Agreement Between
BioClonetics Incorporated, Assignor, and
BioClonetics Immunotherapeutic, Inc., Assignee

1. U.S. Patent No. 5,459,060, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV), issued October 17, 1995.
2. U.S. Patent No. 5,777,074, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV), issued July 7, 1998.
3. U.S. Patent No. 6,008,044, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV) and Detection of Antibodies Against Epitope (GCSGKLIC), issued Dec. 18, 1999.
4. U.S. Patent No. 6,083,504, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1 (HIV), issued July 4, 2000.
5. European Patent (EPC) No. 0492560, Human Monoclonal Antibodies Directed Against the Transmembrane Glycoprotein (GP41) of Human Immunodeficiency Virus-1, issued October 10, 2001. This EPC patent is effective in 13 European Countries, namely, Austria, Belgium, Denmark, France, Germany, Great Britain, Italy, Liechtenstein, Luxembourg, Netherlands, Spain, Sweden, and Switzerland.

DAI 452783v.2